Phase II Randomized Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas After One Prior Line of Systemic Therapy or Ineligible to Receive an Anthracycline-based Treatment
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 28 Aug 2017
At a glance
- Drugs Nivolumab (Primary) ; Pazopanib (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- 17 Aug 2017 Planned primary completion date changed from 1 Jun 2020 to 17 Aug 2017.
- 17 Aug 2017 Planned initiation date changed from 1 Oct 2017 to 1 Aug 2017.
- 17 Aug 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.